Patients in Germany Treat Acute Attacks with Firazyr Earlier Than Those Elsewhere with Better Results, Study Finds
Patients in Germany treat acute hereditary angioedema attacks with Firazyr (icatibant) earlier and have fewer severe attacks than do patients in 11 other countries where Firazyr is also approved, a retrospective study shows. The disparity is thought to arise from a easier access to Firazyr in Germany and a public healthcare…